Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | April 08, 2014

Key News and Technology at ACC.14

By Dave Fornell

The biggest news item from the American College of Cardiology (ACC) 63rd Annual Scientific Session was that a transcatheter aortic valve had 26 percent better survival in high-risk patients than surgical valve replacement. This is a big deal, as it shows the promise of transcatheter valve technology to eventually replace open-heart surgical procedures is not a theory out in left field. What is more impressive is the fact that the operators were given three patients to learn how to use the CoreValve device before their fourth and subsequent patients counted in the trial. Despite the relative inexperience with the device and procedure compared to cardiac surgeons, who in most cases have been performing valve replacements for a decade or longer, the fact that the new device outperformed surgery is very impressive. Read more on the trial or watch a video interview with one of the lead investigators.

The major disappointment at ACC.14 was the presentation of the SYMPLICITY HTN-3 renal denervation U.S. pivotal trial. The device used failed to reduce blood pressure a statistically significant amount over a sham procedure, calling into question the future of denervation technology. This session was packed solid with thousands of attendees, who wanted to hear the details and what the future might be for this technology. Read more on the trial or watch a video interview with one of the investigators.

A key late-breaking presentation for cardiac imaging was a combination of five trials that show coronary artery calcium scoring provides an early indication of a patient’s long-term risk for heart disease. Read more on the trial.

A key presentation in electrophysiology was the long-term results from the MADIT-CRT trial, which showed greatly improved outcomes and survival in heart failure patients with left bundle branch block. Read more on the trial.

I walked the exposition show floor and found several new, innovative technologies and on display. I also found some technologies that highlight trends in cardiology, including examples of how to achieve patient engagement and enterprise imaging. Watch the video “DAIC Editor’s Choice for Most Innovative New Technology.”

Related Content

Videos | Heart Failure | October 16, 2020
The late-breaking MitraBridge Study was presented at...
Chest X-ray of a congestive heart failure patient, showing fluid in the lower portions of the lungs and an enlarged heart. Getty Images

Chest X-ray of a congestive heart failure patient, showing fluid in the lower portions of the lungs and an enlarged heart. Getty Images

News | Heart Failure | October 05, 2020
October 5, 2020 — The American College of Cardiology (ACC) says...
The Optimizer Smart System is a pacemaker-like device that improves heart function and reduces debilitating symptoms associated with the disease, including fatigue and shortness of breath.
News | Heart Failure | September 23, 2020
September 23, 2020 – A team of cardiologists at Allegheny General Hospital (AGH), part of Allegheny Health Network (A
The Medtronic Heartware and Abbott Heartmate 3 LVADs and others currently cleared by the FDA might be easier to use in Medicare advanced heart failure patients under new guidelines proposed by CMS. Photo by Dave Fornell

The Medtronic Heartware and Abbott Heartmate 3 LVADs and others currently cleared by the FDA might be easier to use in Medicare advanced heart failure patients under new guidelines proposed by CMS. Photo by Dave Fornell

Feature | Heart Failure | August 21, 2020 | Dave Fornell, Editor
August 21, 2020 — The U.S.
Photo of Eyes Predicts Death and Readmission in Heart Failure Patients. Getty Images.

Photo of Eyes Predicts Death and Readmission in Heart Failure Patients. Getty Images.

News | Heart Failure | August 17, 2020
 
Examples of  allogeneic cardiac cells (also called cardiosphere-derived cells or CDCs).

Examples of allogeneic cardiac cells (also called cardiosphere-derived cells or CDCs), that were used to treat heart attack infarcts to reverse heart failure in the ALLSTAR trial.

News | Heart Failure | August 04, 2020
August 4, 2020 - More than three years after a clinical trial was prematurely ended for failing to show progress in h
News | Heart Failure | July 09, 2020
July 9, 2020 – The Minneapolis Heart Institute Foundation (MHIF) is conducting additional research on a novel hydroge
Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient to treat heart failure..

Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient.

News | Heart Failure | June 23, 2020
June 23, 2020 — The U.S.
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio
News | Heart Failure | March 29, 2020
March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational